Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825.
Scheurer ME, Zhou R, Gilbert MR, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Youssef EF, Stieber VW, Komaki RR, Flickinger JC, Kenyon LC, Robins HI, Hunter GK, Crocker IR, Chao ST, Pugh SL, Armstrong TS.
Scheurer ME, et al. Among authors: hunter gk.
Neurooncol Adv. 2022 Oct 22;4(1):vdac152. doi: 10.1093/noajnl/vdac152. eCollection 2022 Jan-Dec.
Neurooncol Adv. 2022.
PMID: 36299794
Free PMC article.